How the FDA May Kill Millions In the U.S

Forbes, Steve
February 2011
Forbes Asia;Feb2011, Vol. 7 Issue 2, p11
The article discusses issues related to growing bureaucratic approach in the U.S. Food & Drug Administration (FDA). It has been stated that the play-it-safe attitude of the FDA due to interference of the U.S. Congress is creating a devastating and potentially deadly impact on human lives. It has been stated that failure of government regulation has prevented the pharmaceutical industry to develop a reliable new class of antibiotics.


Related Articles

  • FDA's Vancocin Rule-Bend: Generic Floodgate's Future? Osborne, Randy // BioWorld Insight;7/27/2009, Vol. 17 Issue 30, p1 

    The article offers information on the move of ViroPharma to prove that its manufactured drug, vancocin is not highly soluble. It mentions that the medicine is approved by the U.S. Food & Drug Administration (FDA) for the treatment of antibiotic-associated pseudomembranous colitis. It relates...

  • Companies may limit use to vets only. JALONICK, MARRY CLARE // Farm & Dairy;4/3/2014, Vol. 100 Issue 28, pA14 

    The article presents views of the U.S. Food and Drug Administration (FDA) on the decision of pharmaceutical companies to withdraw the use of antibiotics in animals that are used for meat.

  • Tracking Washington.  // MondayMorning;11/21/2011, Vol. 19 Issue 42, p6 

    The article discusses the proposals in the U.S. Congress that would allow drug manufacturers to bypass customary clinical trial requirements before the products are brought to market. The proposals will factor in Congressional talks to reauthorize the fee system used by pharmaceutical companies...

  • FDAAA Boosts Fees, Broadens Disclosure. Wechsler, Jill // BioPharm International;Nov2007, Vol. 20 Issue 11, p14 

    The article focuses on the Food and Drug Administration Amendment Act (FDAAA) that was enacted by the U.S. Congress. It relates that the enactment of the FDAA has allowed for the continuation of the Prescription Drug User Fee program. Moreover, an overview is provided on the changes that was...

  • The balancing act.  // Nature Reviews Drug Discovery;Sep2003, Vol. 2 Issue 9, p683 

    Regulatory changes in the United States signal good times ahead for the producers of generic drugs. Meanwhile, more facts are needed to ensure that the incentives for innovation remain.

  • Drug safety: FDA pushes for manufacturers to take greater responsibility.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p32 

    The article reports on the response of the U.S. Food and Drug Administration (FDA) to the demands from the Congress. The agency believes that drug manufacturers need to take responsibility for their products' safety because it feels that the demands seem unrealistic, stating that it is unable to...

  • House Passes Legislation On FDA Reform.  // Bioworld Week;9/24/2007, Vol. 15 Issue 39, p5 

    The article reports on the legislation passed by the U.S. House that would give the Food and Drug Administration (FDA) stronger authority to demand, rather than ask, manufacturers to make changes to prescription drug labeling and conduct post-marketing safety studies. The legislation includes...

  • Under scrutiny. Conlan, Michael F. // Drug Topics;6/26/95, Vol. 139 Issue 12, p54 

    Discusses congressional reforms focused on the Food and Drug Administration (FDA). Changes planned for by GOP legislators include privatization and contracting out of agency functions; Safety and efficacy standards; FDA's veto power; FDA mission in the agenda of the Pharmaceutical Research and...

  • How do alternative treatments fit into traditional medicine? Nash, Karen // Dermatology Times;Sep2005, Vol. 26 Issue 9, p14 

    Focuses on the need for the U.S. Congress and Food and Drug Administration to get involve with pharmaceutical industry and scientists to investigate the effectiveness of alternative medicine. Citations of the different reaction of dermatologists on the issue; Reasons of the people to take...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics